Evidence map›Paper›PMID 23263360›Full record

ArticleJournal of molecular modeling2013

Rational design of the survivin/CDK4 complex by combining protein-protein docking and molecular dynamics simulations.

Jana Selent, Agnieszka A Kaczor, Ramon Guixà-González, Pau Carrió, Manuel Pastor, Cristian Obiol-Pardo

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Jana SelentResearch Programme on Biomedical Informatics (GRIB), IMIM/Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain.
Agnieszka A Kaczor
Ramon Guixà-González
Pau Carrió
Manuel Pastor
Cristian Obiol-Pardo
Pompeu Fabra University · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survivin, the smallest inhibitor of apoptosis protein (IAP), is a valid target for cancer research. It mediates both the apoptosis pathway and the cell cycle and has been proposed to form a complex with the cyclin-dependent kinase protein CDK4. The resulting complex transports CDK4 from the cytosol to the nucleus, where CDK4 participates in cell division. Survivin has been recognized as a node protein that interacts with several partners; disruption of the formed complexes can lead to new anticancer compounds. We propose a rational model of the survivin/CDK4 complex that fulfills the experimental evidence and that can be used for structure-based design of inhibitors modifying its interface recognition. In particular, the suggested complex involves the alpha helical domain of survivin and resembles the mode of binding of survivin in the survivin/borealin X-ray structure. The proposed model has been obtained by combining protein-protein docking, fractal-based shape complementarity, electrostatics studies and extensive molecular dynamics simulations.

Indexed as

Binding SitesCell Cycle ProteinsCrystallography, X-RayCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p16HumansInhibitor of Apoptosis ProteinsMolecular Docking SimulationMolecular Dynamics SimulationNeoplasm ProteinsProtein BindingProtein Structure, SecondaryProtein Structure, TertiaryStatic ElectricityStructural Homology, ProteinBIRC5 protein, humanCDCA8 protein, humanCDK4 protein, humanCDK6 protein, humanCell Cycle ProteinsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p16Inhibitor of Apoptosis ProteinsNeoplasm ProteinsSurvivin

Identifiers

PMID23263360
OpenAlexW2048728366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.